Article

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, USA.
Journal of Pediatrics (impact factor: 4.11). 07/2006; 149(1):112-9. DOI:10.1016/j.jpeds.2006.01.052 pp.112-9
Source: PubMed

ABSTRACT To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years.
Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV.
Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found.
Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns.

0 0
 · 
0 Bookmarks
 · 
18 Views
  • Source
    Article: [Attention deficit hyperactivity disorder: the state of the matter and further research approaches].
    E Cardo, M Servera
    [show abstract] [hide abstract]
    ABSTRACT: AIM: This paper is a review on the state of affairs of attention deficit hyperactivity disorder. DEVELOPMENT: In the first section, the authors review the limitations and controversies in the fields of the prevalence, etiology, diagnostic criteria and comorbidities. In the second part, there is an update of the latest findings in the field of the neurobiological bases, the genetic etiology, the relevance of the evaluation of the executive functions and the effectiveness of drug therapies, behavioral and others alternatives therapies. The authors have selected the most relevant recently published bibliography and addressed in a schematic way, disputes or outstanding issues with a greater emphasis on the lines of research more relevant in the near future.
    Revista de neurologia 46(6):365-72. · 0.65 Impact Factor
  • Source
    Article: A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.
    Tracey W Tsang, Michael R Kohn, Daniel F Hermens, Simon D Clarke, C Richard Clark, Daryl Efron, Noel Cranswick, Chris Lamb, Leanne M Williams
    [show abstract] [hide abstract]
    ABSTRACT: The ACTION study (Attention deficit hyperactivity disorder Controlled Trial Investigation Of a Non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, Atomoxetine, in children and adolescents with attention deficit hyperactivity disorder (ADHD). The primary aims are to examine the efficacy of atomoxetine for improving cognition and emotional function in ADHD and whether any improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of ADHD. This manuscript will describe the methodology and rationale for the ACTION study. Children and adolescents aged 6 - 17 y with ADHD will be enrolled. Clinical interview and validated scales will be used to confirm diagnosis and screen for exclusion criteria, which include concurrent stimulant use, and comorbid psychiatric or neurological conditions other than anxiety. Three assessment sessions will be conducted over the 13-week study period: Session 1 (Baseline, pre-treatment), Session 2 (six weeks, atomoxetine or placebo), and Session 3 (13 weeks, cross-over after one-week washout period). The standardized touch-screen battery, "IntegNeuro™", will be used to assess cognitive and emotional function. The primary measure of response will be symptom ratings, while quality of life will be a secondary outcome. Logistic regression will be used to determine predictors of treatment response, while repeated measures of analysis will determine any differences in effect of atomoxetine and placebo. The methodology for the ACTION study has been detailed. The ACTION study is the first controlled trial to investigate the efficacy of atomoxetine using objective cognitive and emotional function markers, and whether these objective measures predict outcomes with atomoxetine in ADHD with and without comorbid anxiety. First enrollment was in March 2008. The outcomes of this study will be a significant step towards a 'personalized medicine' (and therefore a more efficient) approach to ADHD treatment. Australian and New Zealand Clinical Trials Registry ANZCTRN12607000535471.
    Trials 03/2011; 12:77. · 2.02 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

-scored total scores
 
13 atomoxetine studies
 
2 years
 
2-year treatment period
 
3 months
 
601 atomoxetine-treated subjects
 
7 open-label
 
adolescent subjects
 
adverse events
 
American Psychiatric Association's Diagnostic
 
attention-deficit/hyperactivity disorder
 
blood pressure
 
clinically significant abnormalities
 
first 3 months
 
laboratory values
 
parent version
 
Statistical Manual
 
subjects age 12
 
Two-year data
 
unexpected safety concerns